Private Insurance Prior Authorization for Spravato

For Canadians with private extended-health benefits, Spravato (intranasal esketamine) is the most likely-covered psychedelic-assisted therapy product through prior authorization. Major Canadian private insurers including Manulife, Sun Life, Green Shield, and the provincial Blue Cross branches generally accept prior-authorization requests for documented TRD (treatment-resistant depression) where Health Canada-approved Spravato indication criteria are met. This pathway is separate from the PSHCP (Public Service Health Care Plan) / Canada Life Form M7520 process for federal public servants, but operates on similar principles. Off-label generic ketamine (IV / IM / sublingual) for psychiatric use is generally not covered by private extended-health plans. Therapy fees (preparation/integration psychotherapy) may be partially covered as standard psychotherapy when delivered by a registered profession. This article walks through the private prior-auth pathway for Spravato in detail, what documentation typically supports successful applications, and how to navigate denials.

Key takeaways

• Spravato is the most likely privately-covered psychedelic-assisted therapy product through prior authorization with Manulife, Sun Life, Green Shield, Blue Cross provincial branches, and other Canadian private insurers.
• Documentation typically required: TRD diagnosis with documented failure of two or more adequate antidepressant trials; Spravato + concurrent oral SSRI/SNRI per Health Canada indication; Janssen Journey-certified clinical setting; psychiatric/specialist prescription.
• Reimbursement levels vary by plan — typically partial coverage with patient out-of-pocket after deductible and co-insurance. Net out-of-pocket often $0–$300 per session for fully approved patients.
• Off-label generic ketamine (IV / IM / sublingual) for psychiatric use is generally not covered — no Canadian approved indication closes private formulary inclusion.
• Therapy fees (preparation/integration psychotherapy) may be partially covered as standard psychotherapy when delivered by Registered Psychologist, Registered Psychotherapist, Registered Clinical Counsellor, or Registered Social Worker (depending on provincial scope).
• Appeals: most insurers have appeal processes; documentation of additional clinical justification, alternative treatment failures, or specialist consultation typically supports successful appeals.
• For PSHCP federal public servants: see PSHCP / Canada Life Spravato Coverage (Form M7520) — the most established Canadian private pathway.
• ATMA CENA's role: supports preparation and integration via coordinated care; ATMA CENA's Janssen Journey certification status should be confirmed at intake.

Why Spravato is the most likely privately-covered psychedelic-assisted therapy product

The structural reason: Spravato is Health Canada-approved. The May 2020 Health Canada approval for treatment-resistant major depressive disorder in adults — in combination with oral SSRI/SNRI, after failure of at least two adequate antidepressant trials in the current depressive episode — created a clear regulatory framework that Canadian private insurers can map to formulary inclusion criteria.

By contrast, off-label generic ketamine for psychiatric use has no Canadian approved indication, which closes the standard private formulary inclusion pathway. Most Canadian private insurers do not cover off-label psychiatric ketamine.

For more detail on the Spravato modality, see Intranasal Ketamine and Spravato.

How private prior authorization works

The general Spravato prior-auth pathway across Canadian private insurers:

1. Establish TRD diagnosis with prescribing physician

Treatment-resistant depression is operationalized as failure of two or more adequate antidepressant trials in the current depressive episode. "Adequate" typically means therapeutic dose for ≥6 weeks. Documentation includes:

• Specific medications tried (SSRIs, SNRIs, atypicals, augmentation strategies)
• Doses and duration
• Reason for discontinuation (lack of response vs intolerable side effects)
• Continued symptoms despite adequate treatment

The prescribing physician (typically psychiatrist) compiles this documentation.

2. Identify Janssen Journey-certified clinical setting

Spravato administration requires a Janssen Journey-certified clinical setting — Health Canada's controlled-distribution program with mandatory ≥2-hour supervised observation post-dose. Canadian providers documented or marketed as Spravato-administering include:

• Royal Ottawa BMO Innovative Clinic for Depression
• Jewish General Hospital Montreal
• Edmonton hospital affiliates
• Numinus locations
• Other psychiatric private practice with Janssen Journey certification

3. Confirm concurrent oral SSRI/SNRI

Spravato's Health Canada-approved indication is specifically Spravato + concurrent oral SSRI/SNRI. Patients on antidepressant taper plans need to coordinate with the prescribing physician.

4. Submit prior-authorization request

The prescribing physician completes the insurer's prior-auth form (varies by insurer) and submits with supporting documentation. Patient typically signs consent for medical-information release.

Specific insurer pathways:

• Manulife: prior-auth request through standard medical claims process; documentation requirements similar across insurers
• Sun Life: prior-auth request through Sun Life claims; may require psychiatric specialist letter
• Green Shield: prior-auth request through Green Shield Canada portal; documentation similar
• Blue Cross provincial branches (Alberta, Manitoba, Atlantic Blue Cross, etc.): each branch has its own prior-auth pathway. Alberta Blue Cross PAT (March 2024) coverage is a separate framework — see Alberta Blue Cross PAT Coverage
• Canada Life PSHCP Form M7520: federal public servants — separate from this article. See PSHCP / Canada Life Spravato Coverage
• Other private insurers (Pacific Blue Cross, Industrial Alliance, etc.): generally similar prior-auth frameworks

5. Insurer review

Review timelines vary: typically 5–15 business days. Complex cases or appeal scenarios may extend the timeline.

6. Reimbursement

If approved, reimbursement is at the plan's specific drug-coverage level — typically 80% or higher of approved cost subject to:

• Annual deductible
• Plan coverage maximums (some plans have specific drug-spend caps)
• Co-insurance percentages
• Prior-authorization renewal requirements (some plans require periodic recertification)

Net out-of-pocket for typical patients with prior auth: often $0–$300 per session despite list price ~$800–$900. Specific costs depend on individual plan.

What documentation typically supports successful prior auth

Strong Spravato prior-authorization applications typically include:

• Confirmed TRD diagnosis from prescribing psychiatrist
• Detailed antidepressant trial history: medications, doses, durations, response/non-response, side effects, reasons for discontinuation
• Documentation of failed augmentation strategies: lithium, atypical antipsychotic, T3 — where applicable
• Documentation of failed psychotherapy attempts: trauma-focused, CBT, IPT — where applicable
• Current depression severity: PHQ-9, MADRS, or HAM-D scores
• Treatment plan: Spravato dosing schedule, concurrent oral SSRI/SNRI, monitoring plan
• Provider certification: prescribing physician details; Janssen Journey-certified clinical setting
• Realistic treatment goals: response criteria, expected duration, maintenance plan

When applications are denied

Common reasons for denial:

• Insufficient documentation of antidepressant trial adequacy (dose or duration)
• Lack of Janssen Journey certification at proposed clinical setting
• Plan-specific exclusions
• Prior-authorization criteria not met

Appeals process

Most Canadian private insurers have appeal processes. Documentation that supports successful appeals:

• Additional antidepressant trial detail: more granular dose/duration documentation
• Specialist consultation letter: from the prescribing psychiatrist or another specialist supporting the SAP request rationale
• Documentation of alternative treatment failures: ECT trial, IV ketamine off-label, augmentation strategies
• Updated severity documentation: current PHQ-9, MADRS scores
• Provider verification: Janssen Journey certification

Specialized health-insurance lawyers and patient advocates can support complex appeals.

For the broader appeals framework, see Insurance Appeals When Coverage Is Denied.

Therapy fees coverage

Beyond the drug coverage, therapy fees for preparation and integration psychotherapy may be partially covered through standard psychology benefits in private extended-health plans. Eligibility:

• Therapist must hold a covered professional designation (Registered Psychologist, Registered Psychotherapist, Registered Clinical Counsellor, Registered Social Worker — varies by province)
• Plan-specific psychology benefit maximums (often $500–$2,500/year)
• Direct-billing arrangements vary by clinic and plan

ATMA CENA's preparation and integration sessions can typically be billed through psychology benefits where the delivering therapist has the covered profession scope.

Off-label ketamine — generally not privately covered

For off-label generic ketamine (IV / IM / sublingual) for psychiatric use, the realistic 2026 private insurance picture:

• Not generally on private formularies — no Canadian approved indication
• Therapy fees may be partially covered as standard psychotherapy
• Workers' compensation (WSIB Ontario, WCB Alberta) and VAC coverage frameworks exist for compensable conditions and service-connected veterans respectively — see Workers' Compensation for Psychedelic-Assisted Therapy and VAC Coverage for Psychedelic-Assisted Therapy
• Edmonton Misericordia/Grey Nuns is the AHCIP-covered public ketamine option for ultra-resistant TRD — see Edmonton Misericordia/Grey Nuns Public Ketamine Program

Patients pursuing ATMA CENA's KAT pathway with off-label ketamine typically face out-of-pocket costs at ATMA CENA's published KAT pricing tiers ($1,530–$6,930 per program). See Ketamine Therapy Cost in Canada.

How ATMA CENA supports private-insurance Spravato patients

ATMA CENA's role for private-insurance Spravato-pathway patients:

• ATMA CENA's Janssen Journey certification for direct Spravato administration should be confirmed at intake. Where ATMA CENA is not directly Janssen Journey-certified, the pathway routes to certified providers via the coordinated care model.
• ATMA CENA supports preparation and integration for Spravato-pathway patients regardless of where dosing happens.
• ATMA CENA's KAT services (off-label IM/SL ketamine) are alternative pathways where Spravato prior auth is not approved or where Spravato is not a clinical fit.
• The coordinated care model is particularly valuable for Spravato patients with established psychiatric care relationships.

Frequently asked questions

Which Canadian private insurers cover Spravato? Manulife, Sun Life, Green Shield, Blue Cross provincial branches (with the exception of Alberta Blue Cross PAT which has a separate framework), and other Canadian private insurers generally accept prior-authorization requests for documented TRD.

What's the documentation required? TRD diagnosis with documented failure of two or more adequate antidepressant trials; Spravato + concurrent oral SSRI/SNRI per Health Canada indication; Janssen Journey-certified clinical setting; psychiatric/specialist prescription; current severity documentation.

What's the reimbursement level? Varies by plan — typically partial coverage at 80% or higher of approved cost subject to deductibles, plan maximums, and co-insurance.

Net out-of-pocket per session? Often $0–$300 per session for fully approved patients despite list price ~$800–$900. Specific net costs depend on individual plan.

Does my plan cover Spravato? Check your plan's drug benefits booklet or contact your insurer directly. Most major Canadian private insurers will accept prior-auth requests; specific plan-tier eligibility varies.

What if I'm a federal public servant? PSHCP / Canada Life is your primary pathway via Form M7520. See PSHCP / Canada Life Spravato Coverage.

What if I'm an Albertan with Alberta Blue Cross? Alberta Blue Cross has its PAT (Psychedelic-Assisted Therapy) coverage launched March 2024 which is a separate framework from standard private prior-auth. See Alberta Blue Cross PAT Coverage.

What if my prior auth is denied? Appeal options include resubmitting with additional documentation, specialist consultation letter, alternative treatment failure documentation. Most insurers have appeal processes. See Insurance Appeals When Coverage Is Denied.

Can my therapy fees be covered through psychology benefits? Often yes for the preparation and integration psychotherapy components when delivered by a registered profession (Registered Psychologist, etc.). Direct-billing arrangements vary by clinic and plan.

What about off-label ketamine? Generally not privately covered for psychiatric use. Therapy fees may be partially covered as standard psychotherapy. See Insurance Coverage for Ketamine Therapy.

Can I switch from Spravato to off-label ketamine if Spravato isn't approved? Possibly. Discuss with your prescribing physician. Off-label IV/IM/sublingual ketamine has different access pathways and is typically out-of-pocket through private insurance.

What if I have an HSA (Health Spending Account) through my employer? HSA funds can typically be applied to out-of-pocket Spravato costs that aren't covered through the standard plan. HSA arrangements vary by employer; confirm with HR.

What's the difference between standard Blue Cross prior auth and Alberta Blue Cross PAT coverage? Standard Blue Cross provincial branches generally accept Spravato prior auth for documented TRD. Alberta Blue Cross's March 2024 PAT coverage is a specific psychedelic-assisted therapy benefit framework that initially covered ketamine-assisted therapy with psilocybin/MDMA framed as future potential. Different framework, different scope. See Alberta Blue Cross PAT Coverage.

Sources

1. ATMA CENA — find care near you: https://psychedelic.healthcare/find-care
2. Health Canada DPD — Spravato: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
3. Manulife Health Insurance: https://www.manulife.ca/personal/insurance.html
4. Sun Life Health Insurance: https://www.sunlife.ca/en/insurance/
5. Green Shield Canada: https://www.greenshield.ca/
6. CDA-AMC — Spravato CDEC Final Recommendation: https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0621%20Spravato%20-%20CDEC%20Final%20Recommendation%20December%2018,%202020_for%20posting.pdf

Related articles

• Insurance Coverage for Psychedelic-Assisted Therapy in Canada
• PSHCP / Canada Life Spravato Coverage
• Alberta Blue Cross PAT Coverage
• Provincial Drug Plans for Psychedelic Therapy
• Insurance Appeals When Coverage Is Denied
• Intranasal Ketamine and Spravato
• Insurance Coverage for Ketamine Therapy

Last updated: 2026-05-06